Brain Excitability in Patients With Succinic Semialdehyde Dehydrogenase Deficiency
NCT00132366 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 60
Last updated 2017-07-02
Summary
This study will measure brain excitability in patients with succinic semialdehyde dehydrogenase (SSADH) deficiency, and in their parents. SSADH is a rare inherited disease in which changes in certain brain chemicals affect brain cell activity. Symptoms vary greatly among patients, and may include mental retardation, impaired ability to coordinate movements, and delays in language and speech development. Other symptoms may include poor muscle tone, uncontrolled seizures and other neurological or behavioral abnormalities. Test findings in patients and their parents will be compared with those of healthy normal volunteers.
The following individuals may be eligible for this study: patients with SSADH who are between 5 and 24 years of age; parents of patients who are between 18 and 55 years of age; healthy normal children who are between 10 and 17 years of age; and healthy normal adults who are between 18 and 55 years of age. Candidates are screened with blood and urine tests.
All participants undergo the following:
* Transcranial magnetic stimulation (TMS): This procedure maps brain function. A wire coil is held on the scalp, and a brief electrical current is passed through the coil, creating a magnetic pulse that stimulates the brain. During the stimulation, the subject may be asked to tense certain muscles slightly or perform other simple actions to help position the coil properly. The stimulation may cause a twitch in muscles of the face, arm, or leg, and the subject may hear a click and feel a pulling sensation on the skin under the coil. During the test, electrical activity of muscles is recorded with a computer or other recording device, using electrodes attached to the skin with tape.
* Magnetic resonance imaging (MRI): This test combines a powerful magnet with an advanced computer system and radio waves to produce accurate, detailed pictures of organs and tissues. During the scan, the subject lies on a table in a narrow cylinder containing a magnetic field, wearing ear plugs to muffle loud noises that occur with electrical switching of the magnetic fields. He or she can speak with a staff member via an intercom system at all times during the procedure. In addition to standard MRI, subjects may have newer MRI tests, such as diffusion tensor MRI and magnetic resonance spectroscopy.
In addition to the above, patients and their parents may also undergo the following tests:
* Electroencephalography (EEG): This test records brain waves (electrical activity of the brain). Electrodes are placed on the scalp and brain electrical activity is recorded while the subject lies quietly, breathes deeply, watches flashes of light, or sleeps. Some patients may also have video-EEG monitoring, which involves simultaneous clinical recording using a video camera along with brain wave recording.
* Sleep study and multiple sleep latency onset testing (MSLT): Electrodes are placed on the subject's scalp and remain there while the subject sleeps in the hospital overnight. MSLT is done the next day, starting 2 hours after the subject wakes up from the night's sleep. A total of five 20- to 30-minute naps are recorded, each every 2 hours, to access daytime sleepiness.
* Nerve conduction studies: This test measures the speed with which nerves conduct electrical impulses and the strength of the connection between the nerve and the muscle. A probe is placed on the skin to deliver a small electrical stimulus, and wires taped on the skin record the impulses.
Conditions
- Succinic Semialdehyde
- Dehydrogenase Deficiency
- Diseases
Sponsors & Collaborators
-
National Institute of Neurological Disorders and Stroke (NINDS)
lead NIH
Eligibility
- Min Age
- 5 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2005-08-16
- Primary Completion
- 2008-06-30
- Completion
- 2008-06-30
Countries
- United States
Study Locations
More Related Trials
-
Histidine Oral Supplementation as a Therapeutic Modality for Alzheimer's Disease
NCT06169826 ·Status: WITHDRAWN ·Phase: PHASE4
-
Thalidomide for Patients With Mild to Moderate Alzheimer's Disease
NCT01094340 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD
NCT02423200 ·Status: COMPLETED ·Phase: PHASE2
-
Screening and Evaluation of Patients With Signs and Symptoms of Alzheimer's Disease
NCT00955422 ·Status: COMPLETED
-
Effectiveness of A Nutritional Brain Metabolic Enhancer for Alzheimer Disease
NCT00013923 ·Status: COMPLETED ·Phase: PHASE2
-
Alzheimer's Disease Biomarkers in Cerebrospinal Fluid in Insulin-resistant Men
NCT02010476 ·Status: COMPLETED
-
Attentional Mechanisms in SCD
NCT06002477 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Phase 1 Study Investigating Effects of HTL0009936 on Cognition and BOLD fMRI Signals in Healthy Elderly Subjects
NCT02546310 ·Status: COMPLETED ·Phase: PHASE1
-
CADASIL Disease Discovery
NCT02821780 ·Status: COMPLETED
-
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
NCT04971733 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
NCT00556660 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment
NCT05040217 ·Status: RECRUITING ·Phase: PHASE1
-
Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia
NCT02862210 ·Status: COMPLETED ·Phase: PHASE2
-
An Evaluation of Three Doses of NS 2330 in Patients With Mild to Moderate Dementia of the Alzheimer's Type
NCT00153010 ·Status: COMPLETED ·Phase: PHASE2
-
EEG-cholinergic Index and Clinical Response to Treatment With Cholinesterase Inhibitors
NCT02623764 ·Status: UNKNOWN
-
Effects of Memantine on Magnetic Resonance (MR) Spectroscopy in Subjects at Risk for Alzheimer's Disease
NCT00933608 ·Status: COMPLETED ·Phase: PHASE4
-
Pilot Clinical Study of CT1812 in Mild to Moderate Alzheimer's Disease Using EEG
NCT04735536 ·Status: COMPLETED ·Phase: PHASE2
-
SSRI's and the Rate of Progression From MCI to Dementia
NCT04901494 ·Status: WITHDRAWN
-
Plasma Hydrogen Sulfide as a Biomarker for Alzheimer's Disease and Related Dementias
NCT05060848 ·Status: ACTIVE_NOT_RECRUITING
-
Efficacy And Safety Of CX516 In Elderly Participants With Mild Cognitive Impairment.
NCT00040443 ·Status: COMPLETED ·Phase: PHASE2
-
3-month Study of MSDC-0160 Effects on Brain Glucose Utilization, Cognition & Safety in Subjects With Alzheimer's Disease
NCT01374438 ·Status: COMPLETED ·Phase: PHASE2
-
Enhancing Health and Quality of Life for Individuals With Dementia Through Transitional-State Snacks
NCT05007730 ·Status: COMPLETED ·Phase: NA
-
Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects
NCT00605046 ·Status: TERMINATED ·Phase: PHASE1
-
Effects of Donepezil HCL on Task-Activated fMRI Brain Activation in Healthy Older Adults at Genetic Risk for Alzheimer's Disease
NCT02087865 ·Status: COMPLETED ·Phase: PHASE4
-
Performance of AclarusDx™, a Blood-Based Transcriptomic Test for AD, in US Patients Newly Referred to a Memory Center
NCT01465360 ·Status: COMPLETED